24
Participants
Start Date
August 31, 2012
Primary Completion Date
December 31, 2014
Study Completion Date
March 31, 2015
PX-866
"Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity."
vemurafenib
vemurafenib is a B-Raf enzyme inhibitor
New York University, New York
University of Pittsburgh Cancer Institute, Pittsburgh
University of Pennsylvania, Philadelphia
H. Lee Moffitt Cancer Center, Tampa
Vanderbilt-Ingram Cancer Center, Nashville
Lead Sponsor
Cascadian Therapeutics Inc.
INDUSTRY